These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18077820)

  • 1. The FDA and the IOM report.
    Galson SK
    N Engl J Med; 2007 Dec; 357(24):2520-1; author reply 2521-2. PubMed ID: 18077820
    [No Abstract]   [Full Text] [Related]  

  • 2. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 3. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
    Psaty BM; Meslin EM; Breckenridge A
    JAMA; 2012 Jun; 307(23):2491-2. PubMed ID: 22563032
    [No Abstract]   [Full Text] [Related]  

  • 4. The Institute of Medicine report on the FDA: where is the science?
    Philipson T; Jena AB; Sun E
    Health Econ; 2007 Mar; 16(3):219-21. PubMed ID: 17315264
    [No Abstract]   [Full Text] [Related]  

  • 5. Congress responds to the IOM drug safety report--in full.
    Psaty BM; Korn D
    JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202
    [No Abstract]   [Full Text] [Related]  

  • 6. Protecting the health of the public--Institute of Medicine recommendations on drug safety.
    Psaty BM; Burke SP
    N Engl J Med; 2006 Oct; 355(17):1753-5. PubMed ID: 17030843
    [No Abstract]   [Full Text] [Related]  

  • 7. Sweeping changes, or a sweep under the rug?
    Barie PS
    Surg Infect (Larchmt); 2006 Oct; 7(5):407-8. PubMed ID: 17083306
    [No Abstract]   [Full Text] [Related]  

  • 8. Ethical considerations in studying drug safety--the Institute of Medicine report.
    Mello MM; Goodman SN; Faden RR
    N Engl J Med; 2012 Sep; 367(10):959-64. PubMed ID: 22913661
    [No Abstract]   [Full Text] [Related]  

  • 9. IOM advises FDA on ethics in postmarket safety trials.
    Kuehn BM
    JAMA; 2010 Aug; 304(6):627. PubMed ID: 20699450
    [No Abstract]   [Full Text] [Related]  

  • 10. IOM: congress must reform FDA to improve drug safety.
    Young D
    Am J Health Syst Pharm; 2006 Nov; 63(21):2032, 2034. PubMed ID: 17057032
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA responds to institute of medicine drug safety recommendations--in part.
    Psaty BM; Charo RA
    JAMA; 2007 May; 297(17):1917-20. PubMed ID: 17473302
    [No Abstract]   [Full Text] [Related]  

  • 12. Risks and benefits of risk-management plans.
    Meltzer D
    Health Aff (Millwood); 2007; 26(3):681-3. PubMed ID: 17485744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Institute of Medicine's report on drug safety: constructive and ambitious, but does it go far enough?
    Jones JK
    Clin Pharmacol Ther; 2007 Feb; 81(2):156-8. PubMed ID: 17259940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both Urgency and Balance Needed in Addressing Opioid Epidemic: A Report From the National Academies of Sciences, Engineering, and Medicine.
    Bonnie RJ; Kesselheim AS; Clark DJ
    JAMA; 2017 Aug; 318(5):423-424. PubMed ID: 28715551
    [No Abstract]   [Full Text] [Related]  

  • 15. IOM urges FDA to be more aggressive in monitoring safety of approved drugs.
    Kuehn BM
    JAMA; 2012 Jun; 307(23):2475-6. PubMed ID: 22797430
    [No Abstract]   [Full Text] [Related]  

  • 16. IOM calls for consistent, rigorous approach to drug safety.
    Traynor K
    Am J Health Syst Pharm; 2012 Jun; 69(12):1009-10. PubMed ID: 22644969
    [No Abstract]   [Full Text] [Related]  

  • 17. The report of the Institute of Medicine on drug safety.
    Somberg J
    Am J Ther; 2007; 14(1):1-2. PubMed ID: 17303967
    [No Abstract]   [Full Text] [Related]  

  • 18. IOM: overhaul drug safety monitoring.
    Kuehn BM
    JAMA; 2006 Nov; 296(17):2075-6. PubMed ID: 17077364
    [No Abstract]   [Full Text] [Related]  

  • 19. The FDA in 2006: reasons for optimism.
    Chabner BA; Roberts TG
    Oncologist; 2007 Mar; 12(3):247-9. PubMed ID: 17405888
    [No Abstract]   [Full Text] [Related]  

  • 20. Review and critique of the Institute of Medicine report "the future of drug safety".
    Benet LZ
    Clin Pharmacol Ther; 2007 Feb; 81(2):158-61. PubMed ID: 17259941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.